NCT03277482 2025-05-31
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
Dana-Farber Cancer Institute
Xi'an Jiaotong University
Instituto do Cancer do Estado de São Paulo
Alliance for Clinical Trials in Oncology